ReviewDiabetes2020
Epigenetic Regulation of Hepatic Lipogenesis: Role in Hepatosteatosis and Diabetes.
Review in Diabetes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Egyptian MASLD genetic map; between the leading TM6SF2 gene and role of epigenetic.Journal of applied genetics · 2026Article
- Role of neddylation in diabetes metabolism: potential therapeutic target.Journal of diabetes and metabolic disorders · 2026Review
- Intrauterine Growth-Restricted Female Yucatan Miniature Pig Neonates Fed Parenteral Nutrition Exhibit Early Catch-Up Growth Leading to Obesity and Ectopic Fat Deposition in Adulthood.The Journal of nutrition · 2025Article
- Effects of semaglutide on metabolism and gut microbiota in high-fat diet-induced obese mice.Frontiers in pharmacology · 2025Article
- A genome-wide association study identifies genetic determinants of hemoglobin glycation index with implications across sex and ethnicity.Frontiers in endocrinology · 2024Article
- Retinoid X receptor heterodimers in hepatic function: structural insights and therapeutic potential.Frontiers in pharmacology · 2024Review
- Targeting protein modifications in metabolic diseases: molecular mechanisms and targeted therapies.Signal transduction and targeted therapy · 2023Review
- Comprehensive Analyses of Prognostic Values and Immune Infiltration of KDM3 Gene Family in Hepatocellular Carcinoma.Molecular biotechnology · 2023Article
- Ubiquitin-Specific Proteases (USPs) and Metabolic Disorders.International journal of molecular sciences · 2023Review
- EBNA2 mediates lipid metabolism and tumorigenesis through activation of ATF4 pathway.American journal of cancer research · 2023Article
- Lipogenesis inhibitors: therapeutic opportunities and challenges.Nature reviews. Drug discovery · 2022Review
- Nuclear HMGB1 protects from nonalcoholic fatty liver disease through negative regulation of liver X receptor.Science advances · 2022Article
- Growth performance, fatty acid composition, and lipid metabolism are altered in groupers (Animal nutrition (Zhongguo xu mu shou yi xue hui) · 2022Article
- Effects ofFrontiers in cardiovascular medicine · 2022Article
- Phenolics-Rich Extracts of Dietary Plants as Regulators of Fructose Uptake in Caco-2 Cells via GLUT5 Involvement.Molecules (Basel, Switzerland) · 2021Article
- Histone Deacetylase 1 Reduces Lipogenesis by Suppressing SREBP1 Transcription in Human Sebocyte Cell Line SZ95.International journal of molecular sciences · 2021Article
- Vitamin D and lumisterol derivatives can act on liver X receptors (LXRs).Scientific reports · 2021Article
- Advances in Unhealthy Nutrition and Circadian Dysregulation in Pathophysiology of NAFLD.Frontiers in clinical diabetes and healthcare · 2021Review
- Epigenetics and Beyond: Targeting Histone Methylation to Treat Type 2 Diabetes Mellitus.Frontiers in pharmacology · 2021Review
- Combined Transcriptomic and Lipidomic Analysis Reveals Dysregulated Genes Expression and Lipid Metabolism Profiles in the Early Stage of Fatty Liver Disease in Rats.Frontiers in nutrition · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Hepatosteatosis, which is frequently associated with development of metabolic syndrome and insulin resistance, manifests when triglyceride (TG) input in the liver is greater than TG output, resulting in the excess accumulation of TG. Dysregulation of lipogenesis therefore has the potential to increase lipid accumulation in the liver, leading to insulin resistance and type 2 diabetes. Recently, efforts have been made to examine the epigenetic regulation of metabolism by histone-modifying enzymes that alter chromatin accessibility for activation or repression of transcription. For regulation of lipogenic gene transcription, various known lipogenic transcription factors, such as USF1, ChREBP, and LXR, interact with and recruit specific histone modifiers, directing specificity toward lipogenesis. Alteration or impairment of the functions of these histone modifiers can lead to dysregulation of lipogenesis and thus hepatosteatosis leading to insulin resistance and type 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.